NAARDEN, The Netherlands--(BUSINESS WIRE)--BAC BV, the leading provider of antibody based affinity purification technology, has announced a collaboration with Bristol-Myers Squibb Company (NYSE:BMY) to generate CaptureSelect® affinity ligands for applications in the purification and analysis of a proprietary type of targeted biologic, called Adnectins™. Derived from human fibronectin, Adnectins are engineered using Bristol-Myers Squibb’s proprietary PROfusion™ technology to either block or stimulate the action of specific targets across a broad range of therapeutic areas.
